Zydus receives final approval from the USFDA for Acyclovir Cream

Zydus receives final approval from the USFDA for Acyclovir Cream

The product will be launched shortly in the US market. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India

FPJ Web DeskUpdated: Thursday, March 02, 2023, 03:55 PM IST
article-image
Zydus receives final approval from the USFDA for Acyclovir Cream | Image: Zydus Lifesciences (Representative)

Zydus Lifesciences Limited announced that the company has received final approval from the United States Food and Drug Administration (USFDA) for Acyclovir Cream, via an exchange filing.

Acyclovir belongs to a class of medications known as antivirals. Acyclovir cream is used to treat cold sores (fever blisters; blisters that are caused by a virus called herpes simplex) on the face or lips.

The product will be launched shortly in the US market. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India.

Acyclovir Cream, 5% had annual sales of USD 16.9 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 348 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

RECENT STORIES

Emcure Pharmaceuticals Q4 PAT Up 63% At ₹197 Crore

Emcure Pharmaceuticals Q4 PAT Up 63% At ₹197 Crore

Gokaldas Exports Posts ₹53-Crore Profit In Q4

Gokaldas Exports Posts ₹53-Crore Profit In Q4

India Set To Lead Global Oil Demand Growth Over Next Decade As China Nears Consumption Peak:...

India Set To Lead Global Oil Demand Growth Over Next Decade As China Nears Consumption Peak:...

'SEBI To Issue Final Word On Equity Derivatives Expiry By May-End': Chairman Tuhin Kanta Pandey

'SEBI To Issue Final Word On Equity Derivatives Expiry By May-End': Chairman Tuhin Kanta Pandey

Adani Ports Gets $150 Million Loan From DBS, Signals Return Of Lender Confidence

Adani Ports Gets $150 Million Loan From DBS, Signals Return Of Lender Confidence